Search

Cabotegravir

[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

Inebilizumab

[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

Methyclothiazide

(From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

Eflornithine

[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … a 68% reduction in the risk of death were observed.

Willow bark

Lerodalcibep

[L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia … [L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels.

Elivaldogene autotemcel

[L40298] In September 2022, Skysona was approved by the FDA.[L43247] … It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.

Rosin

In the pharmaceuticals, rosin is used in film forming and coating tablets and enterically administered agents, as well as forming microcapsules and nanoparticles. … Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267].

Vinorelbine

A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. … It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid.

Fenfluramine

from the market in 1997. … [A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal